<?xml version="1.0" encoding="UTF-8"?>
<ref id="B8-medicina-57-00169">
 <label>8.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ansari</surname>
    <given-names>M.A.</given-names>
   </name>
   <name>
    <surname>Jamal</surname>
    <given-names>Q.M.S.</given-names>
   </name>
   <name>
    <surname>Rehman</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Almatroudi</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Alzohairy</surname>
    <given-names>M.A.</given-names>
   </name>
   <name>
    <surname>Alomary</surname>
    <given-names>M.N.</given-names>
   </name>
   <name>
    <surname>Tripathi</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Alharbi</surname>
    <given-names>A.H.</given-names>
   </name>
   <name>
    <surname>Adil</surname>
    <given-names>S.F.</given-names>
   </name>
   <name>
    <surname>Khan</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19</article-title>
  <source>Arab. J. Chem.</source>
  <year>2020</year>
  <volume>13</volume>
  <fpage>8069</fpage>
  <lpage>8079</lpage>
  <pub-id pub-id-type="doi">10.1016/j.arabjc.2020.09.037</pub-id>
 </element-citation>
</ref>
